Combining a cannabinoid with a serotonin drug synergistically prevented seizures in rats

WIN55,212-2 (CB1 agonist at 2 mg/kg) and RO60-0175 (5-HT2B/2C agonist at 3 mg/kg) were ineffective alone against EEG seizures but combined they reduced seizure incidence, severity, and increased latency to seizure onset. The effect was blocked by CB1 and 5-HT2B antagonists but not by 5-HT2C or 5-HT2A antagonists, pinpointing the specific receptor interaction.

Video-EEG recording in rats treated with pilocarpine to induce status epilepticus. Tested cannabinoid (WIN) and serotonin (RO) agonists alone and combined, with selective receptor antagonists to identify the mechanism.

This reveals a new synergistic anti-seizure mechanism that could enable lower doses of cannabinoid drugs by combining them with serotonin-targeting agents, potentially reducing side effects while maintaining efficacy.

Drug combinations targeting multiple receptor systems could unlock anti-seizure effects that single drugs cannot achieve. The CB1/5-HT2B synergy represents a new therapeutic avenue for epilepsy that combines two well-studied neuromodulatory systems.

Rat model of status epilepticus may not represent all human epilepsy types. Synthetic cannabinoid used, not CBD or THC. Single dose combinations tested. Translation to clinical use requires human safety and efficacy data.